InflaRx N.V. (NASDAQ:IFRX) Sees Large Growth in Short Interest

Key Points

• InflaRx N.V. experienced a significant increase in short interest in September, rising by 67.3% to 758,400 shares, with a days-to-cover ratio of 1.4 days.
• The stock has a consensus target price of $6.20 with five analysts rating it as a "Buy" and one as a "Sell."
• Recent institutional investments included a 158.3% increase in holdings by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT, highlighting strong institutional interest.

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 758,400 shares, a growth of 67.3% from the August 31st total of 453,200 shares. Based on an average daily trading volume, of 529,300 shares, the days-to-cover ratio is presently 1.4 days. Based on an average daily trading volume, of 529,300 shares, the days-to-cover ratio is presently 1.4 days.

Wall Street Analyst Weigh In

IFRX has been the topic of a number of research reports. HC Wainwright initiated coverage on shares of InflaRx in a report on Tuesday, September 2nd. They set a "buy" rating and a $6.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of InflaRx in a report on Saturday, September 27th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $6.20.

Institutional Investors Weigh In On InflaRx

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC boosted its stake in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after purchasing an additional 7,616 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of InflaRx during the first quarter valued at $38,000. Concurrent Investment Advisors LLC purchased a new position in InflaRx in the 2nd quarter worth about $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock worth $118,000 after buying an additional 91,927 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in InflaRx during the second quarter valued at about $262,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

InflaRx Stock Performance

InflaRx stock traded down $0.02 during trading on Monday, reaching $1.56. The company had a trading volume of 308,237 shares, compared to its average volume of 462,666. The firm has a market capitalization of $104.79 million, a price-to-earnings ratio of -1.97 and a beta of 1.40. InflaRx has a 12-month low of $0.71 and a 12-month high of $2.82. The stock's 50 day moving average price is $1.17 and its two-hundred day moving average price is $1.13.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). The firm had revenue of $0.05 million during the quarter, compared to analysts' expectations of $0.02 million. As a group, research analysts expect that InflaRx will post -1.04 earnings per share for the current year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.